Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231854 | 0.80 | HTR2A (0.51) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8447696 | 0.78 | HTR2A (0.43) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL21027978 | 0.78 | HTR2A (0.45) | HTR2AHTR2CNOTUMALDH1A1SIGMAR1 | |
| SCHEMBL8654307 | 0.77 | HTR2A (0.43) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL13279281 | 0.75 | HTR2A (0.40) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL18229904 | 0.75 | HTR2A (0.42) | HTR2AHTR2CNOTUMSIGMAR1JAK3 | |
| SCHEMBL18229914 | 0.75 | HTR2A (0.42) | HTR2AHTR2CNOTUMSIGMAR1JAK3 | |
| SCHEMBL18229903 | 0.75 | HTR2A (0.42) | HTR2AHTR2CNOTUMSIGMAR1JAK3 | |
| SCHEMBL13448722 | 0.74 | HTR2A (0.42) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL8658423 | 0.74 | HTR2A (0.43) | HTR2AHTR2CNOTUMSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| EP-3294712-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-8637541-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-8637541-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-08-18 | — | — | US | disclosed |
| WO-2010085820-A2 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| WO-2010031182-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2010-03-25 | — | — | WO | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-5721245-A | ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MC2R, HRH2, PTGDR | HTR2A 154/4885HTR2C 236/4885NOTUM 4041/4885 |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | HTR2A 604/4885HTR2C 749/4885NOTUM 3876/4885 |
| US-20110201641-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, MTNR1B, MTNR1A | HTR2A 33/4885HTR2C 83/4885NOTUM 2653/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | HTR2A 772/4885HTR2C 1011/4885NOTUM 3644/4885 |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | HTR2A 80/4885HTR2C 81/4885NOTUM 1772/4885 |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1012/4885HTR2C 642/4885NOTUM 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.